Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor + Local Therapy in Oligometastatic ESCC
NCT06190782Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2022
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 3 years. Started Sep 2022; status: recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06190782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190782.